What this pack is
DuoPlavin is the brand name in this record; clopidogrel and acetylsalicylic acid film-coated tablets is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
DuoPlavinGeneric nameclopidogrel and acetylsalicylic acid film-coated tablets
How this medicine works
Clopidogrel's active metabolite irreversibly inhibits the platelet ADP P2Y12 pathway; aspirin irreversibly inhibits platelet cyclooxygenase and lowers thromboxane A2. The two pathways explain the fixed combination and why another antithrombotic medicine must not be added casually.
Read source: Europe ↗Current regulatory record · reviewed 2026-09-06More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- DuoPlavin
- Generic name
- clopidogrel and acetylsalicylic acid film-coated tablets
- Dosage-form class
- DuoPlavin film-coated tablets combine clopidogrel 75 mg with aspirin 75 mg or 100 mg in one tablet. The two figures belong to two active ingredients, not one 150 mg or 175 mg medicine; this page does not infer splitting permission from the oval shape.
- Route
- Oral (fixed two-ingredient product-identity field)
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
15 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 14-tablet blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/001
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 14 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 28-tablet blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/002
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 28 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 30 × 1-tablet unit-dose blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/003
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 30 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 50 × 1-tablet unit-dose blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/004
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 50 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 84-tablet blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/005
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 84 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 90 × 1-tablet unit-dose blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/006
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 90 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 100 × 1-tablet unit-dose blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/007
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 100 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 75 mg per tablet; 30-tablet blister carton; not one 150 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/015
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 75 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 75 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 30 tablets per pack
- Labelled appearance
- yellow · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A75The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 14-tablet blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/008
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 14 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 28-tablet blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/009
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 28 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 30 × 1-tablet unit-dose blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/010
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 30 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 50 × 1-tablet unit-dose blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/011
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 50 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 84-tablet blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/012
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 84 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 90 × 1-tablet unit-dose blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/013
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 90 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
EU · Current EMA EU product information (updated 11 Jun 2026)
Clopidogrel 75 mg plus aspirin 100 mg per tablet; 100 × 1-tablet unit-dose blister carton; not one 175 mg medicine
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- EU/1/10/619/014
- Form and route
- DuoPlavin clopidogrel 75 mg/aspirin 100 mg film-coated tablet · oral (fixed two-ingredient product-identity field)
- Container
- all-aluminium unit-dose blister carton
- Listing review
- Cited public label display reviewed 2026-09-06; actual marketing, stock and availability are not established.
- clopidogrel (as hydrogen sulphate)
- 75 mglabelled clopidogrel amount in the same tablet; not an individual's tablet count or frequency
- acetylsalicylic acid (aspirin, ASA)
- 100 mglabelled aspirin amount in the same tablet; not a second tablet or an individual's regimen
- Package
- 100 tablets per pack
- Labelled appearance
- light pink · oval, slightly biconvex film-coated tablet; appearance is not authentication · imprint C75 / A100The cited source does not establish permission to split this presentation
PACKAGE-VISUAL STATUS
Official text supports colour and imprint checks; no exact pack image means an explicit blank
The 75/75 mg tablet is yellow and marked C75/A75; the 75/100 mg tablet is light pink and marked C75/A100. Colour, shape, imprint, blister or a web screenshot is only a clue and cannot establish authenticity; no similar pack substitutes for an unavailable exact official pack image.
LABEL READING · NOT A PRESCRIPTION
DuoPlavin enlarged label: two ingredients in one tablet—check duplication and bleeding first
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
In 75/75 and 75/100, the first 75 mg is clopidogrel and the second figure is aspirin in that same tablet. The page explains ingredients, packs, warning signals and care boundaries; it does not generate individual tablet counts, stopping/switching, missed-use or perioperative plans.
- This tablet already contains aspirin and clopidogrel. Review prescriptions, OTC pain/cold products, supplements and actual packs together. Another aspirin, PLAVIX/clopidogrel, antiplatelet, oral anticoagulant, heparin, thrombolytic or NSAID may increase bleeding risk; self-separating times does not remove that risk.
- Vomiting blood or coffee-ground material, black or bloody stool, persistent or uncontrolled bleeding, sudden severe headache with awareness/speech/limb change, fainting, breathing difficulty or severe allergy requires prompt local medical care; severe acute features require emergency help.
- Tell physicians and dentists about DuoPlavin before surgery, dental work or another invasive procedure. Do not stop it from a web page; the responsible team must decide timing from both thrombotic and bleeding risks.
- Severe kidney or liver problems, active bleeding or peptic ulcer, aspirin/NSAID allergy or related asthma, pregnancy, prior falls/bleeding, or co-listing of an SSRI, omeprazole/esomeprazole, rifampicin or similar medicines requires priority professional review of the current label.
- Each tablet contains lactose 7 mg (75/75) or 8 mg (75/100) and hydrogenated castor oil 3.3 mg; the latter may cause stomach upset or diarrhoea. Excipient differences support exact-product allergy/tolerance review and do not prove that an originator is always better.
- The official product information provides no public self-splitting permission used by this page. An oval shape is not a score or equal-division instruction; swallowing difficulty needs pharmacist review of the exact product and an appropriate option.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkEMA · European Union / European Economic Area · Regulatory product record or EU product information · 2026-09-06
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- European Union / European Economic Area · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeEMA: current EU DuoPlavin product information and electronic leaflet (75 mg/75 mg and 75 mg/100 mg; updated 11 Jun 2026) ↗Current regulatory record · reviewed 2026-09-06
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- EMA · European Union / European Economic Area · Regulatory product record or EU product information · 2026-09-06EMA: current EU EPAR for DuoPlavin (EMEA/H/C/001143; product information updated 11 Jun 2026) ↗Current regulatory record · reviewed 2026-09-06
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about DuoPlavin (clopidogrel and acetylsalicylic acid film-coated tablets). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
DuoPlavin is the brand in this record and clopidogrel and acetylsalicylic acid film-coated tablets is the active-ingredient name. Check both with the dosage form (DuoPlavin film-coated tablets combine clopidogrel 75 mg with aspirin 75 mg or 100 mg in one tablet. The two figures belong to two active ingredients, not one 150 mg or 175 mg medicine; this page does not infer splitting permission from the oval shape.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- EMA: current EU DuoPlavin product information and electronic leaflet (75 mg/75 mg and 75 mg/100 mg; updated 11 Jun 2026) ↗Current regulatory record · reviewed 2026-09-06
- EMA: current EU EPAR for DuoPlavin (EMEA/H/C/001143; product information updated 11 Jun 2026) ↗Current regulatory record · reviewed 2026-09-06
HOW IT WORKS · NOT A TREATMENT PLAN
Why one tablet uses two antiplatelet pathways: additive action also raises the priority of bleeding review
- CYP2C19 contributes to clopidogrel activation. The label notes lower active-metabolite exposure and platelet effect in poor metabolisers and the availability of genotype tests. This does not mean everyone needs whole-genome screening or permit a website to adjust tablet counts from genes.
- CYP2C19 inhibitors such as omeprazole and esomeprazole may reduce clopidogrel active metabolite, while strong inducers may increase active metabolite and bleeding risk. Review must use the exact medicine, amount, indication and complete list; the site does not generate a universal separation schedule.
- DuoPlavin, single-ingredient PLAVIX, aspirin alone, AGGRENOX, BRILINTA, EFFIENT, PLETAL and anticoagulants are not one medicine that can be interchanged by a shared antithrombotic purpose or total milligrams.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- EMA: current EU EPAR for DuoPlavin (EMEA/H/C/001143; product information updated 11 Jun 2026) ↗Current regulatory record · reviewed 2026-09-06
- EMA: current EU DuoPlavin product information and electronic leaflet (75 mg/75 mg and 75 mg/100 mg; updated 11 Jun 2026) ↗Current regulatory record · reviewed 2026-09-06
- EMA: public medicine overview for DuoPlavin ↗Current regulatory record · reviewed 2026-09-06
SOURCE-TRACEABLE ARCHIVE
DuoPlavinclopidogrel and acetylsalicylic acid film-coated tablets
This page links to public primary-source material for DuoPlavin. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
EU central authorisation
The current EMA EPAR lists 14 Mar 2010 as the authorisation date for DuoPlavin EMEA/H/C/001143.
EMA: current EU EPAR for DuoPlavin (EMEA/H/C/001143; product information updated 11 Jun 2026) ↗EMA product information updated
The current product information consolidates both strengths, warnings, interactions, excipients, appearance and pack authorisation numbers in one official document.
EMA: current EU DuoPlavin product information and electronic leaflet (75 mg/75 mg and 75 mg/100 mg; updated 11 Jun 2026) ↗Public-source review
EPAR, product information and public overview were checked item by item; the separate withdrawn application EMEA/H/C/000874 was not treated as the current product.
EMA: current EU EPAR for DuoPlavin (EMEA/H/C/001143; product information updated 11 Jun 2026) ↗
MARKET SCOPE
Market-record boundary
European Union
Current centrally authorised recordFifteen pack authorisation numbers come from current product information; not all pack sizes may be marketed, so authorisation numbers are not live inventory.
Mainland China, United States, Japan and other markets
Current local record not establishedEU names, packs or shared ingredients do not establish local approval, brand, reference status, supply, reimbursement, price or interchangeability.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Is 75/100 mg one 175 mg medicine?
No. Seventy-five mg is clopidogrel and 100 mg is aspirin in that same tablet. The two active ingredients must remain separate and must not be summed for comparison with any 175 mg product.
Can aspirin or PLAVIX be added when taking DuoPlavin?
Do not add one yourself. DuoPlavin already contains both ingredients. Have a pharmacist or clinician review every prescription, OTC product and pack, and do not self-stop when possible duplication is found.
Can I stop it for a few days before surgery or dental work?
A website cannot set the number of stopping days. Tell the responsible clinician and dentist in advance so they can balance the procedure, bleeding risk and thrombotic risk.
Do I need CYP2C19 or whole-genome testing?
The label confirms a CYP2C19 role in clopidogrel activation and available genotype tests, but it does not support a website requiring whole-genome screening for everyone. The treating team should decide from the indication, prior events, interactions and local guidance.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.